In hematologic malignancies, the antitumor activity of mivavotinib may be the result of direct inhibition of SYK/FLT3 signaling within the malignant cell, whereas in solid tumors, inhibition of SYK/FLT3 by mivavotinib was predicted to reduce cell populations of MDSCs in the TIME to prevent tumor immune escape. Here, SYK is linked to neoplasm.